A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia

Introduction. Empirical antibiotic therapy in neutropenic patients presenting with fever plays a significant role in reducing mortality related to infection. Empirical therapies with broad-spectrum intravenous bactericidal, anti-pseudomonal antibiotics are accepted treatments for febrile neutropenic patients. The aim of this study was to compare the efficacy of piperacillin-tazobactam (PIP-TAZO) and cefoperozone-sulbactam (CS) therapies in adult patients with haematological malignancies presenting with neutropenic fever in a prospective study design. Methodology. Patients with haematological malignancies (leukaemia, lymphoma, multiple myeloma, and myelodysplastic syndrome) were recruited from June 2010-May 2013. Participants were over 18 years old, with an absolute neutrophil count (ANC) of less than 500/mm(3) following chemotherapy or expected to have an ANC less than 500/mm3 in the first 48 h post-chemotherapy, and with an oral body temperature >= 38.3 degrees C at a single measurement or 38.0 degrees C after 1-h monitoring. Patients were randomised to the two treatment groups. The initial empirical therapy comprised PIP-TAZO (4.5 g/6 h/day, IV) and CS (2 g/8 h/day, IV). Results. The overall success rate was 61% with CS and 49% with PIP-TAZO (p = 0.247). Factors affecting the treatment success included a neutrophil count < 100/mm(3), being in the relapse/refractory stage of malignancy, and the presence of a microbiologically documented infection (p < 0.05). Conclusion. PIP-TAZO and CS monotherapies are equally effective and safe for the empirical treatment of febrile neutropenic patients.

Dergi Adı REVISTA ESPANOLA DE QUIMIOTERAPIA
Dergi Cilt Bilgisi 29
Dergi Sayısı 2
Sayfalar 69 - 75
Yayın Yılı 2016
Eser Adı
[dc.title]
A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia
Yazar
[dc.contributor.author]
Aynioglu, Aynur
Yazar
[dc.contributor.author]
Mutlu, Birsen
Yazar
[dc.contributor.author]
Hacihanefioglu, Abdullah
Yayın Yılı
[dc.date.issued]
2016
Yayıncı
[dc.publisher]
SOCIEDAD ESPANOLA QUIMIOTERAPIA
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Introduction. Empirical antibiotic therapy in neutropenic patients presenting with fever plays a significant role in reducing mortality related to infection. Empirical therapies with broad-spectrum intravenous bactericidal, anti-pseudomonal antibiotics are accepted treatments for febrile neutropenic patients. The aim of this study was to compare the efficacy of piperacillin-tazobactam (PIP-TAZO) and cefoperozone-sulbactam (CS) therapies in adult patients with haematological malignancies presenting with neutropenic fever in a prospective study design. Methodology. Patients with haematological malignancies (leukaemia, lymphoma, multiple myeloma, and myelodysplastic syndrome) were recruited from June 2010-May 2013. Participants were over 18 years old, with an absolute neutrophil count (ANC) of less than 500/mm(3) following chemotherapy or expected to have an ANC less than 500/mm3 in the first 48 h post-chemotherapy, and with an oral body temperature >= 38.3 degrees C at a single measurement or 38.0 degrees C after 1-h monitoring. Patients were randomised to the two treatment groups. The initial empirical therapy comprised PIP-TAZO (4.5 g/6 h/day, IV) and CS (2 g/8 h/day, IV). Results. The overall success rate was 61% with CS and 49% with PIP-TAZO (p = 0.247). Factors affecting the treatment success included a neutrophil count < 100/mm(3), being in the relapse/refractory stage of malignancy, and the presence of a microbiologically documented infection (p < 0.05). Conclusion. PIP-TAZO and CS monotherapies are equally effective and safe for the empirical treatment of febrile neutropenic patients.
Açıklama
[dc.description]
WOS: 000385278200002
Açıklama
[dc.description]
PubMed: 26888338
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Cefoperozone-sulbactam
Konu Başlıkları
[dc.subject]
febrile neutropenia
Konu Başlıkları
[dc.subject]
haematological malignancy
Konu Başlıkları
[dc.subject]
monotherapy
Konu Başlıkları
[dc.subject]
piperacillin-tazobactam
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0214-3429
ISSN
[dc.identifier.issn]
1988-9518
İlk Sayfa Sayısı
[dc.identifier.startpage]
69
Son Sayfa Sayısı
[dc.identifier.endpage]
75
Dergi Adı
[dc.relation.journal]
REVISTA ESPANOLA DE QUIMIOTERAPIA
Dergi Sayısı
[dc.identifier.issue]
2
Dergi Cilt Bilgisi
[dc.identifier.volume]
29
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/1941
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
14
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
28 Şubat 2024 17:30
Google Kontrol
Tıklayınız
neutropenic patients treatment PIP-TAZO neutrophil haematological malignancies success Patients empirical febrile degrees infection therapies presenting therapy Empirical comprised initial single groups measurement randomised monitoring Introduction effective equally monotherapies Conclusion documented microbiologically presence malignancy relapse/refractory 100/mm(3)
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms